Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: a randomised, double-blind, placebo-controlled, phase 2a trial

医学 安慰剂 脂肪肝 内科学 临床终点 随机对照试验 安慰剂对照研究 胃肠病学 外科 双盲 疾病 病理 替代医学
作者
Mazen Noureddin,Shaharyar M. Khan,Francisco R. Portell,Diane K. Jorkasky,Jameel Dennis,Omer Khan,L. E. B. Johansson,Edvin Johansson,Arun J. Sanyal
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:8 (12): 1094-1105 被引量:41
标识
DOI:10.1016/s2468-1253(23)00198-x
摘要

Background HU6 is a controlled metabolic accelerator that is metabolised in the liver to the mitochondrial uncoupler 2,4-dinitrophenol and increases substrate utilisation so that fat and other carbon sources are oxidised in the body rather than accumulated. We aimed to assess the safety and efficacy of HU6 compared with placebo in people with non-alcoholic fatty liver disease (NAFLD) and high BMI. Methods This randomised, double-blind, placebo-controlled, phase 2a trial was done at a single community site in the USA. Adults (aged 28–65 years) with a BMI of 28–45 kg/m2, a FibroScan controlled attenuation parameter score of more than 270 decibels per metre, and at least 8% liver fat by MRI-proton density fat fraction (MRI-PDFF) were randomly assigned (1:1:1:1) to receive, under fasting conditions, either once-daily HU6 100 mg, HU6 300 mg, HU6 450 mg, or matching placebo by oral administration for 61 days. Randomisation was blocked (groups of four) and stratified by baseline glycated haemoglobin (<5·7% vs ≥5·7%; 39 mmol/mol). All participants and study personnel involved with outcome assessments were masked to treatment assignment. The primary endpoint was the relative change in liver fat content from baseline to day 61, as assessed by MRI-PDFF, and was analysed in the full analysis set (FAS), which comprised all participants who were randomly assigned, received at least one dose of treatment, and had less than 4·5 kg of weight gain or weight loss from the time of screening to day 1 of treatment. The safety population included all participants who were randomly assigned and received at least one dose of study drug. This study was registered at ClinicalTrials.gov, NCT04874233, and is complete. Findings Between April 28, 2021, and Nov 29, 2021, 506 participants were assessed for eligibility and 80 adults (39 [49%] women and 41 [51%] men) were enrolled and randomly assigned to placebo (n=20), HU6 150 mg (n=20), HU6 300 mg (n=21), or HU6 450 mg (n=19). One participant in the HU6 450 mg group was excluded from the FAS due to weight gain. Relative mean change in liver fat content from baseline to day 61 was –26·8% (SD 17·4) for the HU6 150 mg group, –35·6% (13·8) for the HU6 300 mg group, –33·0% (18·4) for the HU6 450 mg group, and 5·4% (19·8) for the placebo group. Three people treated with HU6 (two treated with 150 mg and one treated with 300 mg) and two people treated with placebo discontinued treatment due to treatment-emergent adverse events (TEAEs). No serious TEAEs were reported. In those treated with HU6, flushing (19 [32%] participants), diarrhoea (15 [25%] participants), and palpitations (seven [12%] participants) were the most frequently reported TEAEs (in the placebo group, two [10%] participants had flushing, none had diarrhoea, and one [5%] had palpitations). There were no deaths. Interpretation HU6 could be a promising pharmacological agent for treating patients with obesity and NAFLD and its metabolic complications. Funding Rivus Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被Leo采纳,获得10
刚刚
精明念瑶发布了新的文献求助10
1秒前
1秒前
1秒前
2秒前
2秒前
2秒前
3秒前
3秒前
3秒前
秒速五厘米的应助被lsh采纳,获得20
4秒前
MST发布了新的文献求助10
4秒前
吐泡泡完成签到,获得积分10
4秒前
Clover完成签到,获得积分20
4秒前
科研通AI6.3的应助被鼻毛好胜采纳,获得10
5秒前
风趣健柏发布了新的文献求助10
5秒前
拼搏幻竹完成签到 ,获得积分10
6秒前
Uuonnggi发布了新的文献求助10
6秒前
zhangyq发布了新的文献求助10
6秒前
7秒前
追寻思雁发布了新的文献求助10
7秒前
7秒前
jr发布了新的文献求助10
7秒前
7秒前
小迷鹿发布了新的文献求助10
8秒前
6666发布了新的文献求助50
8秒前
四方发布了新的文献求助10
8秒前
8秒前
Qingsic发布了新的文献求助10
8秒前
FashionBoy的应助被微血管采纳,获得10
8秒前
8秒前
9秒前
SS发布了新的文献求助10
9秒前
amo完成签到,获得积分10
10秒前
ding发布了新的文献求助10
10秒前
万能图书馆的应助被大尾巴鱼采纳,获得10
10秒前
深情安青的应助被灵巧的嚣采纳,获得100
10秒前
MST发布了新的文献求助10
11秒前
lingling发布了新的文献求助10
12秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187652
求助须知:如何正确求助?哪些是违规求助? 9575758
关于积分的说明 21842805
捐赠科研通 7785538
什么是DOI,文献DOI怎么找? 3435073
关于科研通互助平台的介绍 2559480
邀请新用户注册赠送积分活动 2481963